People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture Risk

ConditionOsteoporosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age70+
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

About this trial

The aim of the Walk BEST study is to provide evidence that it is feasible to implement the technology assisted gait- focused walking program Walk-BEST™ in older adults with osteoporosis, and that this program is acceptable to this population.

Eligibility criteria

Qualifiers

men and women 70 years and older

able to walk independently with or without a walking aid

experienced a prior fracture after the age of 40, OR two falls in the past 12 months, OR who have a bone mineral density test (done as part of routine clinical evaluation) with a T-score < -2.5, OR on a Health Canada-approved anti-osteoporosis medication (oral or intravenous bisphosphonate, denosumab, teriparatide, or romozosumab) to reduce fracture risk or on a bisphosphonate drug holiday (planned treatment interruption)

Disqualifiers

fracture sustained in the past 12 months

unable to walk unsupervised because of active medical or neurocognitive reasons

unable to provide informed consent, or cannot communicate in English or French

Trial design

Treatments tested in this trial

  • Device: Heel2Toe[TM] sensor
  • Technology-assisted therapeutic walking program

Treatment groups

28 Participants
are divided into 2 treatment groups